Dancann Pharma

Summary: Group Key Figures Q4-2024

* Earnings before interest, taxes, depreciation, and amortization

** Earnings before interest and taxes

Number of Shares 31.12.2024 - 3.991.052.390 (141.626.688)

Result per share = Result for the period / weighted average number of shares

Equity ratio = Equity / Total assets

Financial highlights from the 12 months (January to December) of the year (2024):

Revenue (NET) - up by 27.8% YoY

(from 6.07 MDKK to 7.76 MDKK)

Sales - up by 18.5% YoY

(from 14,366 units to 17,027 units)

EBITDA - up by 63.8% YoY

(from -12.88 MDKK to -4.66 MDKK)

CEO, Jeppe Krog Rasmussen, comments:

-          This past year has been pivotal for our organization. It brought many opportunities and challenges that have further shaped our Company’s trajectory. While we have seen strong progress in several key areas, we have also faced intensified competition and regulatory complexities.

Read the full Q4-2024 report to gain insights into our strategic progress in public affairs, the unlocking of financial potential through the sale of BP1 and cost reductions in investor relations, the impact of market competition on financial performance, a revised guidance overview with updated expectations for 2025 and 2026, as well as the current status of product approvals.

For a comprehensive overview, access the full report.

For further information, please contact:

Jeppe Krog Rasmussen, CEO

E-mail: jkr@dancann.com

About DanCann Pharma A/S

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen/Stockholm.

For more information, visit: www.dancann.com

Forward-looking-statement:

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

This disclosure contains information that DanCann Pharma A/S is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 17-02-2025.